Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models

BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and... BAC SYMPOSIUM BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models David C. Christiani, MD,* William Pao, MD, PhD,†‡ James C. DeMartini, DVM, PhD,§ R. Ilona Linnoila, MD, Alvin M. Malkinson, PhD,¶ Amir Onn, MD,# Katerina A. Politi, PhD,** Michael Sharp, MD,†† and Kwok-Kim, MD, PhD‡‡ improved animal models, which will enable development of more Introduction: Human bronchioloalveolar carcinoma (BAC) is a effective treatments against the disease. disease with an evolving definition. “Pure” BAC, characterized by a Key Words: Bronchioloalveolar carcinoma, Preclinical models, bronchioloalveolar growth pattern and no evidence of stromal, Epidemiology, Pathogenesis, Lung cancer. vascular, or pleural invasion, represents only 2 to 6% of non-small cell lung cancer (NSCLC) cases, but up to 20% of NSCLC cases (J Thorac Oncol. 2006;1: S2–S7) may contain elements of BAC. This imprecise definition makes it difficult to perform epidemiologic analyses or to generate accurate animal models. However, because BAC appears to behave clinically he definition of the disease entity known as human bron- differently from adenocarcinoma, a better understanding of this Tchioloalveolar carcinoma (BAC) is evolving. Classically, disease entity is imperative. BAC is considered a subtype of pulmonary adenocarcinoma, Methods/Results: At the BAC Consensus Conference in 2004, our involving http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models

Kim, Kwok-
Journal of Thoracic Oncology , Volume 1 – Nov 1, 2006
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/bac-consensus-conference-november-4-ndash-6-2004-colon-epidemiology-SDLTHv1CBE

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

BAC SYMPOSIUM BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models David C. Christiani, MD,* William Pao, MD, PhD,†‡ James C. DeMartini, DVM, PhD,§ R. Ilona Linnoila, MD, Alvin M. Malkinson, PhD,¶ Amir Onn, MD,# Katerina A. Politi, PhD,** Michael Sharp, MD,†† and Kwok-Kim, MD, PhD‡‡ improved animal models, which will enable development of more Introduction: Human bronchioloalveolar carcinoma (BAC) is a effective treatments against the disease. disease with an evolving definition. “Pure” BAC, characterized by a Key Words: Bronchioloalveolar carcinoma, Preclinical models, bronchioloalveolar growth pattern and no evidence of stromal, Epidemiology, Pathogenesis, Lung cancer. vascular, or pleural invasion, represents only 2 to 6% of non-small cell lung cancer (NSCLC) cases, but up to 20% of NSCLC cases (J Thorac Oncol. 2006;1: S2–S7) may contain elements of BAC. This imprecise definition makes it difficult to perform epidemiologic analyses or to generate accurate animal models. However, because BAC appears to behave clinically he definition of the disease entity known as human bron- differently from adenocarcinoma, a better understanding of this Tchioloalveolar carcinoma (BAC) is evolving. Classically, disease entity is imperative. BAC is considered a subtype of pulmonary adenocarcinoma, Methods/Results: At the BAC Consensus Conference in 2004, our involving

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2006

There are no references for this article.